Notes

Blind to Opinion? Young Children Do Not Count on that Sunk Fees Lead to Unreasonable Selections.
An outbreak of COVID-19 in Wuhan, China caused by SARS-CoV-2 has led to a serious epidemic in China and other countries, resulting in worldwide concern. With the active efforts from prevention and control, the quantity of discharged patients is escalating. How to manage these patients normatively is still challenging. We hereby reported an asymptomatic discharged patient with COVID-19 who was retested positive for SARS-CoV-2, which arouses concern regarding the present discharge standard of COVID-19. OBJECTIVE Our purpose was to explore the impact of atmospheric pollutants on the incidence of tuberculosis and provide new ideas for the prevention and control of tuberculosis in the future. METHODS We explored the relationship between air pollutants and meteorological factors, as well as between air pollutants and heating through Spearman correlation analysis and rank sum test. Additionally, we analyzed the relationship between air pollutants and tuberculosis incidence using the general additive model. Statistical analysis results at the P less then 0.05 level were considered significant. RESULTS Three months after exposure to air pollutants (PM2.5, SO2, NO2 and CO), tuberculosis incidence increased. However, tuberculosis incidence increased 9 months after exposure to PM10. The single pollutant model showed when concentrations of PM2.5, PM10, SO2, NO2, CO and O3 increased by 1 μg/m3 (or 1 mg/m3), the number of tuberculosis cases would increase 0.09%, 0.08%, 0.58%, 0.42%, 6.9% and 0.57%, respectively. The optimal multi-pollutant model was a two-factor model (PM10+NO2). CONCLUSION Air pollutants including PM2.5, PM10, SO2, NO2, CO and O3 increased the risk of tuberculosis. Few studies have been conducted in this area of research, especially regarding the mechanism; thus, the results of this study should contribute to our understanding of TB incidence and prompt additional research. In chronic polyneuropathies associated with hematologic malignancy (HM) the optimal treatment management is primarily focused on the HM, but the parallel response of the neuropathy is still unclear. Rituximab is a recognized therapeutic choice in anti-MAG antibody polyneuropathy, that might be useful also in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) with HM. The efficacy of immunochemotherapy, which is the standard approach to malignant lymphoproliferative diseases, has been poorly investigated in polyneuropathies. We describe a six-months combined bendamustine-rituximab (BR) treatment in nine patients affected by CIDP or paraproteinemic IgM neuropathies with antibodies to peripheral nerve antigens in course of malignant HM. All patients had a long-lasting response with an average relapse free-survival (RFS) time of 31.5 months. Clinical improvement was evident at 6 months from the beginning of therapy, even earlier in 6/9 patients ( less then 2 months). Two patients dramatically improved the disabling attitudinal and intentional tremor and pathogenic autoantibodies significantly declined in 4/5 patients. Neurological relapses occurred in three patients after a mean of 38 months of sustained stability, even if HM remitted. In such cases rituximab was administered but was associated with a shorter RFS time (1 year) compared to the previous BR scheme (3 years). In our case series, the combined BR regimen was a valid option in immune-mediated neuropathies associated with HM. Moreover, in some patients BR scheme allowed an earlier response and a long-lasting improvement than rituximab alone. Antibiotic abuse and the resulting resistance to antibiotics are serious problems faced by the world. Methods for fast and precise detection of bacterial infections are in urgent need. Here, we report a sensitive and selective probe for diagnosis and treatment of Gram-positive bacterial infection. The probe is made of self-assembling short peptide as the skeleton, a luminogen with aggregation-induced emission (AIEgen) as the responsive fluorescence turn-on motif and vancomycin as the targeting group. In vitro assembly of the probe can turn on its fluorescence and simultaneously enhance reactive oxygen species (ROS) generation. The probe shows great selectivity and sensitivity to Gram-positive bacteria detection in vitro by targeted self-assembly on bacterial surface. In vivo imaging studies of a myositis-bearing BALB/c nude mice model indicate that the probe is suitable for diagnosis and treatment of Gram-positive bacterial infection. The integration of AIEgen and self-assembling peptides represents a potential strategy for disease diagnosis and treatment. The effort of incorporating therapeutic drugs with imaging agents has been one of the mainstreams of nanomedicine, which holds great promise in cancer treatment in terms of monitoring therapeutic drug activity and evaluating prognostic index. However, it is still technically challenging to develop nanomedicine endowing a spatiotemporally controllable mechanism of drug release and activatable imaging capability. Here, we developed a yolk-shell type of GSH-responsive nanovesicles (NVs) in which therapeutic drug (Doxorubicin, DOX) and magnetic resonance imaging (MRI) contrast agent (ultrasmall paramagnetic iron oxide nanoparticles, USPIO NPs) formed complexes (denoted as USD) and were encapsulated inside the NVs. The formation of USD complexes is mediated by both the electrostatic adsorption between DOX and poly(acrylic acid) (PAA) polymers and the DOX-iron coordination effect on USPIO NPs. The obtained USD NVs showed a unique yolk-shell structure with restrained drug activity and quenched T1 MRI contrast ability which, on the other hand, can respond to glutathione (GSH) and lead to drug release and T1 contrast activation in a spatiotemporally concurrent manner. Furthermore, the USD NVs exhibited great potential to kill HCT116 cancer cells in vitro and effectively inhibit the tumor growth in vivo. https://www.selleckchem.com/products/d-galactose.html This study may shed light on the design of sophisticated nanotheranostics in precision nanomedicine. Published by Elsevier Ltd.X-ray irradiation-induced toxicity to gastrointestinal tract become a significant clinical problem when using radiotherapy for treating abdominal tumors neighbored to gastrointestinal tissue, which not only often prevents these tumors from receiving a definitive therapeutic dose but also causes a series of gastrointestinal diseases, such as anorexia, abdominal pain, diarrhea and hematochezia. And thus it seriously reduces the therapeutic outcome and life quality of patients. Therefore, the development of gastrointestinal radioprotectors is essential. However, the commercial gastrointestinal radioprotectors in clinical are still rare. In view of this, we prepared bovine serum albumin (BSA) modified graphdiyne (GDY) nanoparticles (GDY-BSA NPs) and for the first time studied its gastrointestinal radioprotection ability. The unique advantages of GDY nanomaterial, including high free radical scavenging ability, good chemical stability in gastric acid condition, relatively longer residence time in gastrointestinal tract and good biosafety under oral administration, provide the favorable prerequisites for it to be used as the gastrointestinal radioprotector.
Homepage: https://www.selleckchem.com/products/d-galactose.html